Current and predicted cost of metastatic renal cell carcinoma in Finland

Author： Purmonen Timo   Nuttunen Päivi   Vuorinen Riikka   Pyrhönen Seppo   Kataja Vesa   Kellokumpu-Lehtinen Pirkko  

Publisher： Informa Healthcare

ISSN： 0284-186X

Source： Acta Oncologica, Vol.49, Iss.6, 2010-08, pp. : 837-843

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Current Strategy in the Treatment of Metastatic Renal Cell Carcinoma

By  

Current Cancer Therapy Reviews, Vol. 1, Iss. 2, 2005-06 ,pp. : 127-137

Bentham Science Publishers

Access to resources Recommend Favorite

Sunitinib for metastatic renal cell carcinoma

By Mukherji Deborah   Larkin James   Pickering Lisa  

Future Oncology, Vol. 6, Iss. 9, 2010-09 ,pp. : 1377-1385

Future Medicine

Access to resources Recommend Favorite

Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma

By  

Cancer Medicine, Vol. 7, Iss. 1, 2018-01 ,pp. : 75-86

John Wiley & Sons Inc

Access to resources Recommend Favorite

Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives

By Santoni Matteo   De Tursi Michele   Felici Alessandra   Lo Re Giovanni   Ricotta Riccardo   Ruggeri Enzo Maria   Sabbatini Roberto   Santini Daniele   Vaccaro Vanja   Milella Michele  

Expert Review of Anticancer Therapy, Vol. 13, Iss. 6, 2013-06 ,pp. : 697-709

Informa Healthcare

Access to resources Recommend Favorite

Prognostic Factors of Immunotherapy in Metastatic Renal Cell Carcinoma

By Padrik Peeter  

Medical Oncology, Vol. 20, Iss. 4, 2003-12 ,pp. : 325-334

Humana Press, Inc

Access to resources Recommend Favorite